FGFR1 and lymphoid neoplasm: Furthermore, futibatinib has demonstrated clinical efficacy in patients harboring FGFR2-fusion-driven cholangiocarcinoma, and is in clinical trials to assess its efficacy in the treatment of solid or myeloid and lymphoid neoplasms with FGFR1 re-arrangements (NCT04189445) [38].